MedTrace Logo

Longitudinal Study of Brain Amyloid imaGing in MEMENTO

NCT02164643 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 448

Last updated 2022-02-03

No results posted yet for this study

Summary

A Multicenter national longitudinal cohort study including at least 800 individuals consecutively recruited from French Research Memory Centers and followed-up over 24 month and included in Memento.

Conditions

  • Alzheimer's Disease (AD) and Related Disorders

Interventions

DRUG

Flutemetamol (18F)

DRUG

Florbetapir (18F)

Sponsors & Collaborators

  • Fondation Plan Alzheimer

    collaborator OTHER

  • GE Healthcare

    collaborator INDUSTRY

  • Avid Radiopharmaceuticals

    collaborator INDUSTRY

  • University Hospital, Bordeaux

    lead OTHER

Principal Investigators

  • Genevieve CHENE, Prof · CIC-EC7 - ISPED - CHU de Bodeaux

  • Geneviève CHENE, Prof · CIC-EC7 - ISPED - CHU de Bordeaux

  • Carole DUFOUIL, Director · CIC-EC7 - ISPED - CHU de Bordeaux

  • Florence PASQUIER, Prof · Head of Lille Memory Clinic, CHRU Lille

  • Marie-Odile HABERT, Prof · Head of Molecular Imaging Work package for the Center for Image Acquisition and Processing - CHU Pitié-Salpêtrière, AP-HP

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-06-10
Primary Completion
2019-10-09
Completion
2019-10-09

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02164643 on ClinicalTrials.gov